SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-23-032230
Filing Date
2023-09-14
Accepted
2023-09-14 06:27:00
Documents
97
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 6-K inpha-20230630_d2.htm   iXBRL 6-K 11344
2 EX-99.1 exh_991masterprhyveninnate.htm EX-99.1 224718
3 EX-99.2 inpha-20230630.htm   iXBRL EX-99.2 1396664
9 headerenjpga.jpg GRAPHIC 26615
  Complete submission text file 0001628280-23-032230.txt   9143295

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inpha-20230630.xsd EX-101.SCH 101034
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT inpha-20230630_cal.xml EX-101.CAL 112385
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT inpha-20230630_def.xml EX-101.DEF 332700
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inpha-20230630_lab.xml EX-101.LAB 815546
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inpha-20230630_pre.xml EX-101.PRE 537774
91 EXTRACTED XBRL INSTANCE DOCUMENT inpha-20230630_d2_htm.xml XML 1550192
Mailing Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE I0 13009
Business Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE I0 13009 33430303030
Innate Pharma SA (Filer) CIK: 0001598599 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39084 | Film No.: 231254000
SIC: 2836 Biological Products, (No Diagnostic Substances)